普乐沙福联合G-CSF在浆细胞疾病自体造血干细胞动员中的疗效与安全性分析
该回顾性研究纳入2018年1月至2019年12月北京大学人民医院49例接受普乐沙福联合G-CSF动员的浆细胞疾病患者,一次采集成功率95.9%,两次累积成功率100%,肾功能不全者亦获较高成功率,主要不良反应为乏力、失眠、腹痛等。
要点
- 普乐沙福联合G-CSF动员一次采集成功率95.9%,两次累积成功率100%。
- 16例肾功能不全患者中第1天采集成功5例(31.3%)。
- 37例患者行auto-HSCT,中性粒细胞中位植活11(8~13)d。
核心结论
- 普乐沙福联合G-CSF用于浆细胞疾病患者自体造血干细胞动员成功率高、不良反应少,肾功能不全患者亦具有较高动员成功率。
研究设计与样本
- 回顾性分析2018年1月至2019年12月北京大学人民医院接受普乐沙福联合G-CSF动员的连续浆细胞疾病病例,共纳入49例。
主要发现
- 49例中MM 39例(79.6%)、淀粉样变性8例(16.3%)、MGRS 2例(4.1%),肾功能不全16例(32.7%),既往其他方案采集失败7例(14.3%)。
- 中位采集次数1(1~3)次,中位采集天数2(1~3)d,一次采集成功47例(95.9%),两次采集累积成功率100%。
- 16例肾功能不全患者中第1天采集成功5例(31.3%),需第2天采集8例(50%),需第3天采集3例(18.8%)。
- 37例行auto-HSCT,白细胞中位植活时间11(8~13)d,血小板中位植活时间11(9~26)d。
临床怎么用
- 浆细胞疾病患者自体造血干细胞动员可考虑普乐沙福联合G-CSF方案,肾功能不全者亦可应用并需关注采集天数。
- 动员后需监测乏力、失眠、腹痛、腹泻、头晕、关节痛等不良反应。
局限性
- 为单中心回顾性研究,样本量49例,结果需更大样本前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the effect and safety of plerixafor combined with G-CSF mobilization in plasma cell disease. Methods: The clinical baseline data, success rate of collection, and adverse reactions of consecutive cases of plasma cell disease were analyzed retrospectively, where the patients received plerixafor combined with G-CSF for autologous hematopoietic stem cell mobilization in Peking University People's Hospital from January 2018 to December 2019. Results: Forty-nine patients with plasma disease were included, of which 39 (79.6% ) were multiple myeloma, 8 (16.3% ) were amyloidosis, and 2 (4.1% ) were monoclonal gammopathy of renal significance. A total of 16 patients (32.7% ) had renal insufficiency, and 7 patients (14.3% ) had previous collection failure. The median times of apheresis was 1 (1-3) , median days of apheresis was 2 (1-3) days, 47 patients (95.9% ) were successfully collected for once, and the success rate of collection for twice was 100% after using plerixafor for mobilization. In 16 patients with renal insufficiency, collection was successful in 5 patients (31.3% ) on the first day, while aphresis was required in 8 patients (50% ) on the second day and 3 (18.8% ) on the third day. The main adverse reactions were fatigue, insomnia, abdominal pain, diarrhea, dizziness, and arthralgia. A total of 37 patients underwent autologous hematopoietic stem cell transplantation with 11 (8-13) days for neutrophil engraftment, and 11 (9-26) days for platelet engraftment. Conclusions: Plerixafor combined with G-CSF has a high success rate in mobilizaion of autologous hematopoietic stem cells in patients with plasma cell disease with minimum side effects, even in patients with renal insufficiency. 目的: 分析普乐沙福联合G-CSF在浆细胞疾病自体造血干细胞中动员的效果及安全性。 方法: 回顾性分析2018年1月至2019年12月在北京大学人民医院使用普乐沙福联合G-CSF进行自体造血干细胞动员的浆细胞疾病患者的基线临床资料、采集成功率及不良反应。 结果: 共纳入49例浆细胞疾病患者,多发性骨髓瘤(MM)39例(79.6%),淀粉样变性8例(16.3%),肾脏意义的单克隆免疫球蛋白沉积病(MGRS)2例(4.1%),肾功能不全16例(32.7%)。其他动员方案既往采集失败患者7例(14.3%)。使用普乐沙福动员后,中位采集次数1(1~3)次,中位采集天数2(1~3)d,一次采集成功47例(95.9%),两次采集累积成功率为100%。在16例肾功能不全的患者中,5例(31.3%)患者第1天采集成功,8例(50%)需要第2天采集,3例(18.8%)需要第3天采集。主要不良反应依次为乏力、失眠、腹痛、腹泻、头晕、关节痛。共37例患者行auto-HSCT,白细胞中位植活时间11(8~13)d,血小板中位植活时间11(9~26)d。 结论: 普乐沙福联合G-CSF用于浆细胞疾病患者自体造血干细胞动员成功率高,不良反应少,即使在肾功能不全的患者中也具有较高的动员成功率。.
引用
- Duan WB, Dou XL, Lei L, et al. [Analysis of the efficacy and safety of plerixafor combined with G-CSF in plasma cell disease mobilization]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33677864. doi:10.3760/cma.j.issn.0253-2727.2021.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。